DNAtrix is a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer.
DNAtrix's platforms leverage the unique characteristics of oncolytic viruses to develop a pipeline of safe and effective therapies for hard to treat cancers that have shown resistance to conventional therapies.
Our platform of clinical stage oncolytic adenoviruses include DNX-2401 (tasadenoturev) and DNX-2440. These viruses have demonstrated the ability to selectively kill tumor cells and trigger long term antitumor immunity.
DNAtrix is continuing to expand its pipeline by developing viruses armed with a variety of potent immunomodulatory molecules designed to unleash robust immune responses against tumors.
DNAtrix has offices located in Houston, Texas and San Diego, California.